<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04759755</url>
  </required_header>
  <id_info>
    <org_study_id>00117438</org_study_id>
    <secondary_id>1R01HL141706-01A1</secondary_id>
    <nct_id>NCT04759755</nct_id>
  </id_info>
  <brief_title>Circadian Timing, Information Processing and Energy Balance Study</brief_title>
  <acronym>TIME</acronym>
  <official_title>Circadian and Sleep Pathways to Cardiometabolic Disease Risk: Role of Neurobehavioral Processes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study design will test biological and behavioral mechanisms in the cross-sectional&#xD;
      analyses and determine the prospective effects of circadian alignment and sleep on changes in&#xD;
      cardiometabolic risk factors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this study is to determine how sleep and circadian rhythm alignment contribute to&#xD;
      neurobehavioral and behavioral mechanisms of cardiometabolic risk. The investigators propose&#xD;
      that circadian misalignment, which is more common among individuals with late sleep timing,&#xD;
      leads to increased consumption of energy dense/prepared foods and to decreased insulin&#xD;
      sensitivity. Short sleep duration and neurobehavioral measures (i.e. delay discounting) may&#xD;
      moderate these associations, thus exacerbating cardiometabolic risk factors. There is&#xD;
      evidence for a direct biological link between circadian misalignment and insulin resistance,&#xD;
      and for a relationship that is mediated through changes in eating behaviors. Insulin&#xD;
      resistance and increased caloric intake over time lead to increased BMI and body fat.&#xD;
&#xD;
      In this study, the investigators will conduct cross-sectional and longitudinal analyses to&#xD;
      determine biological and behavioral mechanisms that link circadian alignment and sleep&#xD;
      duration to changes in cardiometabolic risk over 1 year. This study will identify individual&#xD;
      differences that predict risk for cardiometabolic disorders and suggest potential for sleep,&#xD;
      circadian and neurobehavioral interventions to reduce cardiometabolic risk.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 29, 2019</start_date>
  <completion_date type="Anticipated">May 29, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 29, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin resistance</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured by a frequently sampled IV glucose tolerance test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Eating behaviors</measure>
    <time_frame>12 months</time_frame>
    <description>Healthy Eating Index will be calculated from the Automated Self-Assessment of 24 hour diet recall (ASA-24)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delay discounting</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured by a 10 item adjusting delay discounting measure</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Body mass index</measure>
    <time_frame>12 months</time_frame>
    <description>Height and weight will be measured at screening and 1 year follow-up</description>
  </other_outcome>
  <other_outcome>
    <measure>Metabolic control</measure>
    <time_frame>12 months</time_frame>
    <description>HbA1c will be measured at screening and 12-month follow-up</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Overweight and Obesity</condition>
  <arm_group>
    <arm_group_label>Study participants</arm_group_label>
    <description>18-60 year olds who demonstrate habitual sleep onset time between 10:00 pm-3:00 am and BMI 25-39.9.</description>
  </arm_group>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      Saliva&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        community sample&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Demonstrate habitual sleep onset time between 10:00 pm-3:00 am on actigraphy;&#xD;
&#xD;
          -  able to read and write in English;&#xD;
&#xD;
          -  BMI 25-39.9 (overweight, class one obesity, or class two obesity)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  High risk or presence of sleep disorders (obstructive sleep apnea (OSA), restless legs&#xD;
             syndrome, or insomnia) as assessed by the questionnaires and overnight OSA screening;&#xD;
&#xD;
          -  Diagnosed with diabetes or HbA1c&gt;7 at screening or taking medications known to affect&#xD;
             glucose;&#xD;
&#xD;
          -  History of cognitive or neurological disorders;&#xD;
&#xD;
          -  Presence of major psychiatric disorders, current alcohol or substance abuse as&#xD;
             determined by screening questionnaires or self-report;&#xD;
&#xD;
          -  Unstable or serious medical illness;&#xD;
&#xD;
          -  Overnight shift work or travel over 2 time zones in the past 2 months;&#xD;
&#xD;
          -  Use of hypnotic, stimulant or medications know to affect melatonin concentrations such&#xD;
             as beta blockers, daily NSAIDs;&#xD;
&#xD;
          -  Current smoking;&#xD;
&#xD;
          -  Daily caffeine intake &gt;300 mg;&#xD;
&#xD;
          -  Pregnant or lactating;&#xD;
&#xD;
          -  Currently on a restrictive of special diet.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kelly G Baron, Ph.D.</last_name>
    <phone>8015857588</phone>
    <email>kelly.baron@utah.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrew Rivera</last_name>
    <phone>8015850904</phone>
    <email>andy.rivera@utah.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Rivera</last_name>
      <phone>801-585-0904</phone>
      <email>andy.rivera@utah.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 13, 2021</study_first_submitted>
  <study_first_submitted_qc>February 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Kelly Glazer Baron</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be made available upon request</ipd_description>
    <ipd_time_frame>Data will be available within 1 year of completion of the study and will be available for 1 year</ipd_time_frame>
    <ipd_access_criteria>Written request to the PI</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

